GLS and GOT2 as prognostic biomarkers associated with dendritic cell and immunotherapy response in breast cancer.

ABSTRACT: Breast cancer is the females' most common cancer. Targeting the immune microenvironment is a new and promising treatment method for breast cancer. Nevertheless, only a small section of patients can profit by immunotherapy, and improving the ability to accurately predict the potential for immunotherapy response is still awaiting further exploration. In this study, we found that the key factors of glutamine metabolism, glutaminase 1 (GLS) and mitochondrial aspartate transaminase (GOT2), showed opposite expression patterns in breast cancer samples. Based on the expression level of GLS and GOT2, we divided the breast cancer samples into two clusters: Cluster 2 showed GLS expressed higher and GOT2 expressed lower, whereas Cluster 1 showed GOT2 expressed higher and GLS expressed lower. GSEA show

SUBMITTER: Yang R 

PROVIDER: S-EPMC10792574 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature